---
title: "Augmedix -> Commure Acquisition"
description: "Commure acquired Augmedix, a pioneer in ambient AI medical documentation, for $139M in an all-cash transaction to become the largest AI software provider in healthcare."
date: "2024-07-19"
slug: "augmedix-commure-2024"
published: true
tags: ["ai-documentation", "ambient-intelligence", "healthcare-platform", "roll-up", "2024"]
excerpt: "$139M acquisition of ambient AI medical documentation company with 45% revenue growth"
readTime: "10 min read"
---

# Augmedix -> Commure Acquisition

*Research Completed: 2026-01-03*
*Transaction Status: Closed*

---

## Deal Summary

Commure acquired Augmedix, a pioneer in ambient AI medical documentation, for $139 million in an all-cash transaction. The deal positioned Commure (which had previously merged with Athelas in a $6 billion deal) as "the largest artificial intelligence software provider in healthcare." Augmedix's AI scribe technology, which automatically documents patient encounters, directly addresses clinician burnout and administrative burden.

**Key Metrics:**
| Metric | Value | Confidence | Source |
|--------|-------|------------|--------|
| Deal Value | $139M (equity value) | High | [2024-07-19](https://www.globenewswire.com/news-release/2024/01/05/2804611/0/en/Augmedix-Exits-Calendar-2023-with-Expected-51-Million-in-Annual-Recurring-Revenue.html) |
| Price Per Share | $2.35 | High | [2024-07-19](https://www.fiercehealthcare.com/ai-and-machine-learning/augmedix-acquired-commure-valuation-139-mil) |
| Premium to 30-day VWAP | 169% | High | [2024-07-19](https://www.fiercehealthcare.com/ai-and-machine-learning/augmedix-acquired-commure-valuation-139-mil) |
| FY2023 Revenue | $44.9M | High | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Revenue Growth (FY2023) | 45% YoY | High | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| ARR (Exit 2023) | ~$51M | High | [2024-01-05](https://www.globenewswire.com/news-release/2024/01/05/2804611/0/en/Augmedix-Exits-Calendar-2023-with-Expected-51-Million-in-Annual-Recurring-Revenue.html) |
| Revenue Multiple | ~2.7x FY2023 revenue | Medium | [Calculated: $139M / $51M ARR] |
| Gross Margin (Q4 2023) | 49.3% (+300bps YoY) | High | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Net Revenue Retention | 152% | High | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |

---

## Exit Scenario Analysis

**Pattern Identified**: Healthcare Platform Roll-Up / AI Infrastructure Consolidation

**Why This Classification**:
This acquisition represents consolidation in the healthcare AI infrastructure space. Commure (backed by General Catalyst's Health Assurance initiative) is building a comprehensive healthcare technology platform by acquiring complementary AI capabilities. The deal was about adding ambient AI documentation to Commure's existing health system technology stack.

**Evidence**:
- Commure had previously merged with Athelas (remote patient monitoring, revenue cycle) in 2023 in a deal valued at $6B [2024-07-19](https://www.fiercehealthcare.com/ai-and-machine-learning/augmedix-acquired-commure-valuation-139-mil)
- Both companies had overlapping health system customers (notably HCA Healthcare) [2024-07-23](https://www.beckershospitalreview.com/digital-health/commure-to-acquire-augmedix-in-139m-digital-health-deal.html)
- Commure stated [2024-07-19](https://www.augmedix.com/resources/augmedix-to-join-forces-with-commure) the combination would create "the largest artificial intelligence software provider in healthcare"
- General Catalyst's Health Assurance is a strategic initiative to transform healthcare delivery through technology

**What's Interesting/Unusual About This Deal**:
1. **Significant discount to peak**: Augmedix stock had traded significantly higher before acquisition; the $2.35/share price reflected compressed public market valuations for healthcare tech in 2024
2. **Going private**: This take-private transaction allowed Augmedix to escape public market scrutiny while scaling
3. **Premium paradox**: Despite 169% premium to 30-day VWAP, absolute valuation was modest given 45% growth rate
4. **Customer overlap**: Both companies served HCA Healthcare, suggesting integration synergies

**Confidence in Classification**: High - The roll-up strategy is explicit in Commure's public statements and M&A pattern.

---

## The Deal

### Transaction Structure
- **Deal Type**: All-cash acquisition (take-private)
- **Consideration**: $2.35 per share in cash
- **Premium**: 169% to 30-day volume-weighted average price
- **Announcement Date**: July 19, 2024 [source](https://www.augmedix.com/resources/augmedix-to-join-forces-with-commure)
- **Expected Closing**: Late Q3 or early Q4 2024 [source](https://www.fiercehealthcare.com/ai-and-machine-learning/augmedix-acquired-commure-valuation-139-mil)
- **Structure**: Augmedix to become wholly-owned subsidiary of Commure

### Valuation Analysis
The ~2.7x ARR multiple appears modest for a 45% growth company but reflects several factors:

1. **Public market discount**: Healthcare tech valuations compressed significantly in 2023-2024
2. **Path to profitability unclear**: Despite improving gross margins (49.3%), Augmedix was still burning cash
3. **Competitive pressure**: Ambient AI documentation became crowded (Microsoft/Nuance DAX, Abridge, Nabla)
4. **Private company premium avoided**: Commure acquired at public market distressed valuation

**Comparison to other AI healthcare deals**:
- Microsoft/Nuance: 13-21x revenue (dominant market position, profitable)
- Veradigm/ScienceIO: Not disclosed (private)
- This deal: 2.7x ARR reflects growth-stage company without profitability

### Deal Timeline
| Date | Event |
|------|-------|
| 2013 | Augmedix founded |
| 2020-11 | Augmedix IPO (NASDAQ: AUGX) |
| 2023-11 | Augmedix launches "Augmedix Go" mobile app with ambient AI |
| 2024-01-05 | Augmedix reports $51M ARR exiting 2023 [source](https://www.globenewswire.com/news-release/2024/01/05/2804611/0/en/Augmedix-Exits-Calendar-2023-with-Expected-51-Million-in-Annual-Recurring-Revenue.html) |
| 2024-03-18 | FY2023 results: 45% revenue growth, improved margins [source](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| 2024-05-14 | Stock drops 41% after lowered FY24 guidance [source](https://www.mobihealthnews.com/news/augmedix-stock-falls-41-after-it-lowers-fy24-revenue-guidance) |
| 2024-07-19 | Commure acquisition announced [source](https://www.augmedix.com/resources/augmedix-to-join-forces-with-commure) |
| 2024-Q4 | Deal expected to close |

---

## Target Company

### What They Do
Augmedix pioneered ambient AI medical documentation starting in 2013. Their products:

**Augmedix Live**: Human-assisted remote medical scribing with real-time documentation support. Scribes (initially offshore, later AI-augmented) listen to patient encounters and create documentation in real-time.

**Augmedix Go**: Clinician-controlled mobile app using ambient AI to automatically generate clinical documentation from patient encounters. Launched November 2023 as fully automated alternative to human scribes.

**Key Differentiators**:
- EHR-agnostic integration (works with Epic, Cerner, etc.)
- Combines structured data extraction with narrative documentation
- HIPAA-compliant secure processing

### Scale & Financials
| Metric | Value | Period | Source |
|--------|-------|--------|--------|
| Revenue | $44.9M | FY2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Revenue Growth | 45% YoY | FY2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Q4 2023 Revenue | $12.7M | Q4 2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| ARR | $51M | Exit 2023 | [2024-01-05](https://www.globenewswire.com/news-release/2024/01/05/2804611/0/en/Augmedix-Exits-Calendar-2023-with-Expected-51-Million-in-Annual-Recurring-Revenue.html) |
| Gross Margin | 49.3% | Q4 2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Net Revenue Retention | 152% | FY2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Clinicians in Service Growth | 44% YoY | Q4 2023 | [2024-03-18](https://www.globenewswire.com/news-release/2024/03/18/2848139/0/en/Augmedix-Delivers-45-Revenue-Growth-and-Expanded-Gross-Margins-for-Fourth-Quarter-of-2023.html) |
| Employees | ~1,430 | 2024 | [stockanalysis.com](https://stockanalysis.com/stocks/augx/revenue/) |

**Revenue History**:
| Year | Revenue | Growth |
|------|---------|--------|
| 2019 | $14.1M | 30% |
| 2020 | $16.5M | 17% |
| 2021 | $22.2M | 34% |
| 2022 | $30.9M | 40% |
| 2023 | $44.9M | 45% |

### Funding History
- Founded 2013
- IPO November 2020 (NASDAQ: AUGX)
- Total funding pre-IPO: ~$75M
- Key investors: DCM, Redmile Group, First Round Capital

### The "Crown Jewel"
**Augmedix Go** - The fully automated ambient AI product launched in late 2023. This represented Augmedix's transition from a hybrid human/AI model to a fully AI-driven solution, dramatically improving unit economics and scalability.

The 152% net revenue retention rate indicates strong product-market fit and expansion within existing customers - a key indicator of product value.

---

## Acquirer Context

### Who They Are
Commure is a healthcare technology company building an integrated platform for health systems. The company:
- Merged with Athelas (remote patient monitoring, revenue cycle) in 2023 at $6B valuation
- Backed by General Catalyst's Health Assurance initiative
- Focused on reducing administrative burden and improving clinical workflows
- Has deep relationships with major health systems including HCA Healthcare

**Leadership**:
- Tanay Tandon: CEO (founder of Athelas)
- General Catalyst Health Assurance involvement (Dr. Stephen Klasko as advisor)
- Jefferson Health as founding partner

### Why They Bought This
**Stated Rationale** [2024-07-19](https://www.augmedix.com/resources/augmedix-to-join-forces-with-commure):
- Create "the largest artificial intelligence software provider in healthcare"
- "Streamline the medical documentation ecosystem"
- "Scale our ambient documentation solutions"
- Leverage Commure's "valuable integration capabilities"

**Probable Reality**:
1. **Product gap fill**: Commure/Athelas had remote monitoring and RCM but lacked clinical documentation AI
2. **HCA relationship deepening**: Both companies served HCA; acquisition strengthens that partnership
3. **Competitive positioning**: Ambient AI documentation is becoming table stakes; needed capability to compete
4. **Opportunistic pricing**: Public market distress allowed acquisition at compressed valuation

### Prior M&A Pattern
- 2023: Athelas merger (~$6B combined valuation) - RPM, revenue cycle, lab diagnostics
- 2024: Augmedix ($139M) - Ambient AI documentation

The pattern suggests Commure is building a comprehensive health system technology platform through strategic acquisitions.

---

## Strategic Analysis

### Stated Rationale vs. Probable Reality
Commure frames this as creating an AI powerhouse. The reality is more tactical:

1. **Capability acquisition**: Ambient AI documentation is complex; building in-house would take years
2. **Customer consolidation**: Overlap with HCA allows immediate cross-sell
3. **Valuation arbitrage**: Acquired a 45% growth company at 2.7x revenue due to public market dislocation

### Value Capture Mechanism
Commure's value capture will come from:
1. **Platform bundling**: Sell Augmedix alongside Athelas products to health systems
2. **Margin improvement**: Transition from hybrid human/AI to fully automated (Augmedix Go)
3. **Distribution leverage**: Apply Commure's health system relationships to accelerate Augmedix growth
4. **Integration synergies**: Combine with Athelas infrastructure for operational efficiency

### Competitive Implications
- **Microsoft/Nuance DAX**: Commure now has a competitive product, albeit smaller scale
- **Abridge, Nabla**: Consolidation may trigger more M&A in ambient AI space
- **Health systems**: Get another viable option for clinical AI documentation

---

## Relevance to Dimer Health

**Why This Comp Matters for Dimer:**
1. **AI + clinical services hybrid**: Like Dimer, Augmedix combined AI technology with clinical delivery (initially human scribes, now transitioning to full AI)
2. **Similar scale**: Augmedix at $45-51M revenue is closer to Dimer's trajectory than Nuance's $1.5B
3. **Value-based care adjacent**: Documentation burden is a key barrier to value-based care success; Dimer's AiME addresses similar pain points
4. **Net revenue retention**: Augmedix's 152% NRR demonstrates customer expansion - a metric Dimer should track
5. **Take-private dynamics**: Shows that distressed public valuations can create acquisition opportunities

**Key Differences**:
- Augmedix is pure documentation; Dimer provides clinical services with AI augmentation
- Augmedix sells to physicians/health systems for workflow; Dimer sells outcomes (readmission reduction)
- Augmedix was public; Dimer is private with different liquidity dynamics

**Multiple Implications**:
The 2.7x revenue multiple reflects:
- Growth-stage company without profitability
- Competitive market with well-funded players
- Public market distress creating compressed valuation

For Dimer, this suggests:
- Pure AI documentation companies trade at modest multiples when unprofitable
- Companies with AI + demonstrated outcomes may command premiums
- Dimer's 67% readmission reduction creates differentiated value proposition

---

## Comparable Transactions

| Target | Acquirer | Year | Value | Revenue Multiple | Notes |
|--------|----------|------|-------|------------------|-------|
| Augmedix | Commure | 2024 | $139M | ~2.7x ARR | AI ambient scribe, 45% growth |
| Nuance | Microsoft | 2022 | $19.7B | ~13x revenue | Dominant clinical AI platform |
| ScienceIO | Veradigm | 2024 | $140M | N/A (private) | Healthcare NLP/LLM |
| Livongo | Teladoc | 2020 | $18.5B | ~40x revenue | Chronic care platform |

---

## Research Notes

### Sources
- Augmedix press releases and SEC filings
- Commure/Athelas announcements
- FierceHealthcare, Becker's coverage
- Stock Analysis for historical financials

### Data Gaps & Limitations
- Commure is private; limited financial visibility on acquirer
- Post-acquisition integration status not publicly disclosed
- Exact deal structure details (working capital adjustments, etc.) not available

### Open Questions
- Has Augmedix Go adoption accelerated post-acquisition?
- What is the combined Commure/Athelas/Augmedix revenue run rate?
- How is HCA Healthcare deploying the combined platform?

---

## Tags

`platform-rollup` `ambient-ai` `documentation` `take-private` `clinical-ai` `2024` `growth-stage` `general-catalyst`

---

*Research completed: 2026-01-03*
